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INTRODUCTION 
Oral route is the most convenient and extensively used 
route for drug administration. Over the years the oral 
dosage forms have become sophisticated with 
development of controlled release drug delivery system 
(CRDDS).
1
 
Oral delivery of drugs is one of the easiest route of drug 
delivery due to the ease of administration, patient 
compliance and flexibility in formulation etc. From 
immediate release to site specific delivery, oral dosage 
forms have really progressed. Gastroretentive dosage 
forms significantly extend the period of time, over 
which drug may be released and thus prolong dosing 
intervals and increase patient compliance. Such 
retention systems are important for those drug that are 
degraded in the intestine like antacids or certain 
antibiotics, enzymes that act locally in the stomach. 
This systems can be retained in the stomach and assist 
in improving the oral sustained delivery of drugs that 
have an absorption window in a particular region of the 
gastrointestinal tract, thus ensuring optimal 
bioavailability.
2-3 
The retentive characteristics of the 
dosage form are not significant for the drugs that: They 
Are insoluble in intestinal fluids Act locally to 
overcome these limitations, various approaches have 
been proposed to increase gastric residence of drug 
delivery systems in the upper part of the gastrointestinal 
tract includes floating drug dosage systems (FDDS) 
swelling or expanding systems ,
 
mucoadhesive systems 
, modified-shape systems , high-density system , and 
other delayed gastric emptying devices. Among these 
systems, FDDS have been most commonly used.
4 
During the early 1980s, Marshall and Warren first time 
isolated a spiral, urease producing, flagellate gram-
negative bacterium that was later identified as 
Helicobacter pylori, a causative factor in the etiology of 
peptic ulcer disease. H. pylori appear to be responsible 
for 95% of the cases of gastritis and 65% of gastric 
ulcers. Although most individuals with H. pylori are 
asymptomatic, there is now convincing evidence that 
this bacterium is the major etiologic factor in chronic 
dyspepsia, H. pylori-positive duodenal and gastric 
ulcers and gastric malignancy. Consequently, H. pylori 
eradication is now recognized to be the correct 
approach along with conventional therapies in the 
treatment of the disease. Options that have been 
considered to treat peptic ulcer disease include taking 
drugs such as antacids, H– blockers (antihistaminics), 
antimuscarinics, proton pump inhibitors and 
ABSTACT 
The aim of the current study was to design oral controlled release gastro-retentive drug delivery of Tinidazole. that are designed 
to retain in the stomach for a long time and have developed as a Local drug delivery system for better eradication of 
Helicobacter Pylori in peptic ulcer diseases. Tablets were prepared by direct compression and evaluated for evaluated for 
various physical parameters, Hardness, friability, drug Content, floating ability, Lag time, Swelling Index studies, and in vitro 
dissolution parameters as well as kinetics of release were assessed.  Factorial design for 2 factors at 3 levels each was employed 
to systematically optimize drug release profile and Floating Behavior. Sodium Alginate and Hydroxy Propyl Metheyl Celluiose 
(HPMC K15M) were taken as the independent variables. Response surface plots and contour plots were drawn. Compressed 
tablets exhibited zero order drug release kinetics, resulting in regulated and complete release until 12 hours. Polynomial 
mathematical models, generated for various response variables using multiple linear regression analysis, were found to be 
statistically significant (P < 0.05).Both the polymers had significant effect on the release profiles of the tablets, Besides 
unraveling the effect of the 2 factors on the various response variables, the study helped in finding the optimum Formulation 
„F4‟ with Floating Lag Time (20 sec.) and having controlled release upto 12 hours (99.47%). Meanwhile, sustained profiles of 
drug release were also obtained.  In general, these systems can float in the gastric conditions and control the drug release from 
the tablets. 
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combination therapy for gastritis associated with H. 
pylori. The bacterium is also considered a risk factor for 
the development of gastric adenocarcinoma and 
mucosa-associated lymphoid tissue (MALT) 
lymphoma.
5
  
 
Figure 1: Schematics of H. pylori location within the 
stomach
5 
 
Figure 2:  H.pylori photograph
6
 
The eradication of H. pylori is limited by its unique 
characteristics. Once acquired, it penetrates the gastric 
mucus layer and fixes itself to various phospholipids 
and glycolipids on the epithelial surface. Therefore, the 
organism exclusively resides on the luminal surface of 
the gastric mucosa under the mucus gel layer in the 
acidic environment of the stomach as per Fig. 1 
The bacteria is S-shaped, gram-negative, having flagella 
as shown in fig.12 and measuring 0.5 to 1.0 mm in 
width and 2.5 to 4.0 mm in length. 
For effective H. pylori eradication, therapeutic agents 
have to penetrate the gastric mucus layer to disrupt and 
inhibit the mechanism of colonization. This requires 
targeted drug delivery within the stomach environment. 
Although most antibiotics have very low in vitro 
minimum inhibitory concentrations (MIC) against H. 
pylori , no single antibiotic has been able to eradicate 
this organism effectively. Currently, a drug combination 
namely „„triple therapy‟‟ with bismuth salt, Tinidazole 
and either drugs such as antacids, H -blockers, 
antimuscarinics, tetracycline or amoxycillin with 
healing rates of up to 94% has been successfully used. 
The principle of triple therapy is to attack H. pylori 
luminally as well as systemically. The current treatment 
is based on frequent administration (4 times daily) of 
individual dosage forms of bismuth, tetracycline and 
Tinidazole (Helidac Therapy, consisting of 262.4 mg 
bismuth subsalicylate, 500 mg tetracycline and 250 mg 
Tinidazole). The associated limitations are the complex 
dosing regimen/ frequency, large amount of doses and 
reduced patient compliance. Therefore, a successful 
therapy not only includes the selection of the right drugs 
but also the timing and frequency as well as the 
formulation of the delivery system. 
Recently, gastroretentive systems for treating H.Pylori 
have shown special interest. The prolongation of the 
local availability of the antibacterial agents has been 
reported as an important factor to increase the 
effectiveness of H.pylori treatment. This will ensure a 
high concentration in the gastric mucosa for better 
microbial eradication. Stomach specific floating 
Tinidazole-loaded alginate beads were prepared and 
proved its superiority over Tinidazole suspension in 
local anti-H.pylori therapy. 
 
 
Figure 3: Mucosal damage caused by H.pylori 
5-6 
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Tinidazole,1-[2-(ethylsulfonyl)ethyl]2-methyl-5-
nitroimidazole-1-ethanol, is a nitroimidazole derivative 
with activity against anaerobic protozoa, aerobic and 
microaerophilic bacteria. Common adverse effects of 
Tinidazole involve the gastrointestinal tract and the 
neurological system with high doses. Therefore, 
reduction of side effects of Tinidazole (plasma peak 
levels) while prolonging its action by using controlled 
oral dosage forms is highly desirable. Using various 
polymers can control drug release.  The present study 
aimed to develop controlled release Floating Drug 
Delivery System (FDDS), which will remain in stomach 
for 12 hours while controlling drug release to achieve 
target release profile using a combination of Hydroxy 
Propyl Methyl Cellulose (HPMC K15M) and Sodium 
Alginate as Polymer. 
MATERIALS AND METHODS 
Tinidazole was received as a gift sample from Aarti 
Drug Lab (Mumbai, India) Hydroxy propyl 
methylcellulose K- 15M (HPMC- K15M) was obtained 
from Colorcon Asia Pvt Ltd (Goa, India) and 
Microcrystalline cellulose was received as a gift sample 
from Colorcon Asia Pvt Ltd (Goa, India) . Sodium 
bicarbonate, citric acid, magnesium stearate, talc were 
purchased from Poona Chemicals Laboratories (Pune, 
India). All other chemicals were of analytical grades as 
required. 
Methods 
Effervescent Floating tablets containing Tinidazole 
were prepared by direct compression technique using 
varying concentrations of different grades of polymers 
with Sodium bicarbonate and citric acid. All the 
ingredients were accurately weighed and passed 
through different mesh sieves accordingly. Then, except 
Magnesium stearate all other ingredients were blended 
uniformly in glass mortar After sufficient mixing of 
drug as well as other components, Magnesium stearate 
was added, as post lubricant, and further mixed for 
additional 2-3 minutes. The tablets were compressed 
using rotary tablet machine. The weights of the tablets 
were kept constant for all formulation 
Experimental 
Characterization of Tinidazole 
7
 
Description: The sample of tinidazole was analyzed for 
its nature, color and taste. 
Melting Point: The melting point was taken by open 
capillary method. 
Standard Curve of Tinidazole: Tinidazole has been 
quantitatively analyzed by various techniques. In 
present studies ,Tinidazole was estimated by UV 
Spectrophotometry method. 
Infrared spectra analysis:
8
 Infrared spectrum of 
Tinidazole was determined on Fourier Transform 
Infrared Spectrophotometer (FTIR-4100s) using KBr 
dispersion method. The base line correction was done 
using dried potassium bromide. Then the spectrum of 
dried mixture of drug and potassium bromide was run. 
Differential scanning calorimetry: DSC was 
performed in order to assess the thermotropic properties 
and thermal behavior of Tinidazole. About 5 mg of the 
sample were sealed in the aluminum pans and heated at 
the rate of 10
0
C/min, covering a temperature range of 
40
0
C to 300
0
C under nitrogen atmosphere of flow rate 
100 ml/min. 
Ultraviolet (UV) spectroscopy:
7
 UV spectrum of 25 
μg/ml solution of the drug powder in 0.1 N aqueous 
hydrochloric acid solution was recorded in the range of 
wavelengths from 200nm to 400nm using UV-visible 
Double beam Spectrophotometer (UV-Chemito-2600).
 
 
Figure 4:  UV spectrum of Tinidazole in 0.1 N hydrochloric acid (HCl) 
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Preliminary formulations: 
Before selection of ratio of two polymers that is HPMC 
K15M and Sodium Alginate, low and high levels of 
independent variables should be fixed. This was 
achieved by preparation of some preliminary 
formulations. 
Table 1: Formula for Preliminary Formulation: 
Ingredient 
(mg) 
 
Formulation 
P Q R S 
Tinidazole 300 300 300 300 
Sodium Alginate 50 100 150 200 
HPMC K15M 200 150 100 50 
Total 550 550 550 550 
 
Full Factorial Design: 
Initially Sodium Alginate shows better swelling index 
than HPMC K15M at low concentration but at 12 hours 
HPMC K15M shows high swelling, However matrix 
erosion of HPMC K15M was higher than Sodium 
alginate at low Conc.as a result release of drug from 
HPMC K15M matrix will be higher at than required. 
Hence lower levels of Sodium alginate and higher 
levels of HPMC K15M were selected for factorial 
design. Based on the results obtained with preliminary 
formulations, 3
2
 randomized full factorial designs were 
applied in the present study. In this design 2 factors will 
be evaluated, each at 3 levels, and experimental trials 
will be performed at all 9 possible combinations. The 
amount of polymer that is HPMC K15M and Sodium 
alginate was selected as independent variables. The 
Floating Lag Time, cumulative percent drug released in 
1 & 10 hrs (Q1 & Q10) is selected as dependent 
variables. The probable formulations using 3
2
 
randomized full factorial designs are as shown in the 
Table 3. 
Table 2: Factor levels: 
Coded level -1 0 +1 
HPMC K15M (X1) 130 150 170 
Sodium Alginate 
(X2) 
70 90 110 
 
So the possible combinations of two independent factors having three levels can be given as,    
Independent 
Variable 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
X1 -1 -1 -1 0 0 0 +! +1 +1 
X2 -1 0 +! -1 0 +1 -1 0 +1 
 
Preparation of Floating Tablet of Tinidazole:
8-9
 
Floating tablets each containing 300mg of Tinidazole 
were prepared in different proportions of drug and 
polymer as per given in (Table 3). Different tablet 
formulations were prepared by direct compression 
method 
8,9
. All the powders passed through Sieve No. 
60. The required quantities of medicament and 
polymers were mixed thoroughly in a glass mortar by 
following geometric dilution technique. Then it was 
mixed with sodium bicarbonate and lubricated with 
magnesium stearate (1%w/w) . Then the tablets were 
compressed in compression machine at specified 
pressure with 12mm oval punch. 
 
Table 3: Formulation of Tinidazole floating Tablet 
      Ingredient 
  (mg) 
Formulation 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Tinidazole 300 300 300 300 300 300 300 300 300 
HPMC K15M 130 130 130 150 150 150 170 170 170 
Sodium Alginate 70 90 110 70 90 110 70 90 110 
Sodium-bi carbonate 70 70 70 70 70 70 70 70 70 
Microcrystalline 
Cellulose 
125 95 75 95 75 55 75 55 35 
Magnesium Stearate 15 15 15 15 15 15 15 15 15 
 
Evaluation of Tinidazole floating tablets 
Pre compression parameters
10-11
 
The flow properties of powder blend (before 
compression) were characterized in terms of angle of 
repose, tapped density, bulk density, Carr‟s index and 
Hausner‟s ratio. 
Post compression parameters- 
i) Thickness and diameter 
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Control of physical dimensions of the tablet such as 
thickness and diameter is essential for consumer 
acceptance and tablet uniformity
 12
. The thickness and 
diameter of the tablet was measured using vernier 
callipers. It is expressed in mm. Five tablets were used 
and average values were calculated. 
ii) Hardness 
It indicates the ability of a tablet to withstand 
mechanical shocks while handling. The hardness of the 
tablets was determined using Pfizer hardness tester. The 
value was noted in kg/cm2.Three tablets were randomly 
picked and the hardness of the tablets was determined. 
iii) Weight variation 
Randomly selected twenty tablets were weighed 
individually and together in a single pan balance. The 
average weight was noted and standard deviation was 
calculated 
[13,14].
 The tablet passes the test if not more 
than two tablets fall outside the percentage limit and 
none of the tablet differs by more than double 
percentage limit. 
% Deviation = (Wavg –Winitial) / Wavg × 100 
where, Wavg - average weight of tablet, Winital – 
individual weight of tablet. 
iv) Friability 
Tablet strength was tested by Roche Friabilator. It is 
expressed in percentage (%). Ten tablets were initially 
weighed (W0) and into Friabilator 
[15].
 The Friabilator 
was operated at 25rpm for 4min or run up to 100 
revolutions. The tablets were weighed again (W). The 
% friability was then calculated by: 
% Friability = (W0-W/ W0) ×100 
where, W0 - initial weight of tablets, W - final weight 
of tablets. % Friability of tablets less than 1% are 
considered acceptable. 
v) In vitro buoyancy studies 
The in vitro buoyancy was determined by floating lag 
time method. The tablets were placed in 250 mL beaker 
containing 0.1N HCl 
[16].
 The time required for the 
tablets to rise to the surface and float was determined as 
floating lag time (FLT). The time between introduction 
of dosage form and its buoyancy in 0.1N HCl and the 
time during which the dosage form remain buoyant 
were measured. The total duration of time by which the 
dosage form remains buoyant is called total floating 
time (TFT). 
Swelling study 
Swelling of hydrophilic polymer such as Hydroxy 
Propyl Methyl Cellulose greatly depends upon the 
contents of the stomach and the osmolarity of the 
medium. These eventually influences the release, 
slowing action and the residence time. For each 
formulation, one tablet was weighed and placed in a 
beaker containing 200 ml of distilled water. After each 
hour the tablet was removed from beaker and weighed 
again upto 8 hours. The percentage weight gain by the 
tablet was calculated by using the formula. 
Swelling index (S.I) = {(Wt-Wo)/Wo} x 100 
Where, S.I. = swelling index 
Wt = Weight of tablet at time t 
Wo = Weight of tablet before immersion. 
In vitro drug release 
In vitro drug release of the samples was carried out 
using type-II dissolution apparatus (Paddle type). The 
dissolution medium, 900mL of 0.1N HCl buffer was 
placed into the dissolution flask maintaining the 
temperature of 37±0.5ºC and 50rpm 
17.
 Tablet was 
placed in each vessel and operated the apparatus at 50 
rpm for 12h. Withdrawn 5mL of the sample solution 
from each vessel through 5mL syringes after 1, 2, 4, 6, 
8, 10, 12h and replaced with equal volume of fresh 
dissolution medium previously equilibrated to 37 ± 
0.5°C. Each sample was filtered through 0.45μm filter 
and collected in separate vials. The samples were 
analyzed by UV. The percentage drug released at 
different time points were calculated. The cumulative 
percentage drug release vs time profiles of different 
formulations were Plote. The release data were 
analyzed as per Zero order, First order, Higuchi‟s and 
Peppas equation models 
18.
 
Data analysis:
19-22
 
To analyze the mechanism of release and release rate 
kinetics of the dosage form, the data obtained were 
fitted into Zero order, First order, Higuchi matrix, 
Peppas and Hixson Crowell model using PCP-DISSO – 
v3 software. 
RESULTS AND DISCUSSION 
Pre compression parameters 
All the pre-compressional parameters like bulk density, 
tapped density, angle of repose, Carr‟s index, Hausner‟s 
ratio etc were evaluated and were found to be within the 
limits, indicating the power blend has the required flow 
property for compression. The tablets were prepared by 
direct compression method. In the Preformulation 
studies, compatibility studies were performed using 
FTIR spectrophotometer. The FTIR spectrum of pure 
drug and physical mixture of drug and polymer were 
studied. The peaks obtained in the spectra‟s of each 
formulation correlated with the peaks of pure drug 
spectrum. So it was concluded that no significant 
difference in peak pattern in IR spectrum of drug, 
polymer and the excipients exists. The values obtained 
for the preformulation parameters for the formulations 
F1 to F9 are tabulated in Table 4. 
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Table 4: Pre-compression evaluation of Tinidazole floating tablets 
Formulation 
Code 
Angle of Repose (
o
) 
± SD* 
LBD (gm/cm
2
) 
± SD* 
TBD (gm/cm
2
) 
± SD* 
Compressibility index  
(%) ± SD* 
Hausner’s ratio 
± SD* 
F1 35.53±0.45 0.375±0.006 0.479±0.025 21.42±4.47 1.27±0.07 
F2 36.76±0.55 0.387±.005 0.506±0.005 23.54±1.76 1.30±0.03 
F3 37.13±0.32 0.394±.009 0.504±0.007 21.75±0.62 1.27±0.01 
F4 35.13±0.40 0.349±0.005 0.456±0.004 21.44±0.81 1.30±0.01 
F5 36±0.26 0.366±0.004 0.482±0.004 23.98±1.69 1.31±0.02 
F6 36.53±0.45 0.375±0.004 0.482±0.026 21.97±4.32 1.28±0.06 
F7 33.3±0.81 0.338±0.002 0.440±0.001 23.23±0.44 1.30±0.007 
F8 34.5±0.7 0.337±0.003 0.458±0.003 26.41±0.38 1.35±0.007 
F9 35.13±0.25 0.353±0.005 0.470±0.002 24.92±1.42 1.33±0.02 
* All values are mean ± SD, (n = 3). 
 
Post compression parameters 
Hardness of the tablet was in the range 5.21±0.1 to 
5.37± 0.24 kg/cm2. Weight loss in the friability test was 
in the range 0.24±0.01 to 0.62±0.02% (Table 5). All the 
floating tablets prepared contained Tinidazole within 
the range of 100±4 % of the labeled claim.
 
Table 5:   Post-compression evaluation of Tinidazole floating tablets 
Formulation code                                       Evaluation parameter 
Thickness* ± 
S.D. (mm)       
(n = 5) 
Hardness* ± 
S.D. (kg/cm
2
)  
(n = 5) 
Friability             
(%) 
Average weight 
variation€ 
(n=10) 
Drug content*       
(%) 
F1 3.21±0.01 5.22±0.03 0.47±0.005 697.3±0.35 99.85±0.60 
F2 3.16±0.06 5.23±0.02 0.24±0.01 695.6±0.27 99.3±0.57 
F3 3.24±0.04 5.35±0.03 0.27±0.03 695.0±0.75 98.7±0.98 
F4 3.16±0.04 5.21±0.03 0.26±0.015 698.1±1.02 99.9±0.57 
F5 3.26±0.06 5.32±0.02 0.36±0.03 695.2±0.39 99.1±0.65 
F6 3.18±0.07 5.37±0.02 0.46±0.03 697.2±0.37 98.0±0.98 
F7 3.26±0.08 5.21±0.02 0.62±0.02 692.0± 0.71 99.8±0.99 
F8 3.22±0.05 5.23±0.01 0.52±0.03 697.8±0.6 98.2±0.95 
F9 3.28±0.07 5.28±0.01 0.48±0.03 695.4±0.39 98.0±0.98 
 
In vitro buoyancy studies 
Buoyancy studies were performed using 0.1N HCl 
solution pH1.2 buffer at 37°C (Table 4); the tablets 
floated and remained without disintegration. 
Table 6: In vitro buoyancy studies of Tinidazole 
 
 
B-Brust 
Swelling study 
Swelling study was performed for all the formulations 
F1- F9 for 12h (Table 7). Swelling increases as the time 
passes because the polymer gradually absorbs water due 
to hydrophilicity of polymer. 
Table 7:  Swelling Index of Tinidazole 
 
Formulation 
code 
Floating lag time 
(sec) 
Total floating 
duration 
( hours) 
F1 16 12 
F2 19 12 
F3 23 12 
F4 20 12 
F5 24 12 
F6 30 12 
F7 28 12 +B 
F8 36 12 
F9 42 12 
Formulation code Percent hydration or       
swelling index In hours 
4 8 12 
F1 12 28 42 
F2 42 63 79 
F3 54 73 84 
F4 22 38 52 
F5 52 63 79 
F6 61 78 86 
F7 27 43 55 
F8 52 63 80 
F9 61 78 89 
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Swelling index of blended formulation depicts the 
swellable nature of HPMC K15M and Sodium Alginate 
as shown in Table no 7. Both the polymers are 
hydrophilic in nature. As the concentration of polymers 
increases, swelling index also increase. On comparison 
of swelling index of formulation F1, F2 and F3, all 
contains equal amount of HPMC K15M, swelling index 
increases from F1 to F2 which indicates that swelling 
index depends on concentration of Sodium Alginate, 
increase the concentration of Sodium Alginate more 
will be swelling, higher the retardation of drug release. 
Same pattern was observed in case of Formulation F4, 
F5, F6 and in case of F7, F8, F9. In case of Formulation 
F1, F4 and F7, as the concentration of HPMC K15M 
increased, matrix erosion was found to be increased.
 
In vitro drug release 
Preliminary formulation: 
Table 8: Drug release profile for Preliminary formulations: 
  
From the in-vitro results it was observed that as the concentration of Sod. Alginate increases, the release rate of 
Tinidazole from the formulations reduces which indicates release retardant nature of Sod. Alginate as shown in Table 8. 
 
Figure 5: In vitro drug release from preliminary formulation 
Table 9: In vitro drug release from blended formulation: 
 
Drug release from Formulation F1 was found 99.63 ± 
4.610 at 10 hours. This was attributed to fact that 
formulation F1 contains 70 mg of Sodium Alginate. 
Formulation F2 and F3 showed drug release slower than 
F1 because both contains 90 mg and 110 mg of Sodium 
Alginate respectively as shown in Fig .Concentration of 
HPMC K15M was equal in all three formulations. So 
Sodium Alginate retards the release of drug from 
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Formulation 
Code 
Percent drug release at time     (hr) 
1 2 4 6 8 10 12 
P 48.03 56.80 61.117 69.543 83.267 96.064 97.506 
Q 46.027 54.955 60.345 65.681 77.8 93.819 95.165 
R 43.107 51.269 57.640 62.294 72.976 89.553 93.378 
S 39.855 49.583 55.945 63.508 67.776 84.408 88.288 
 
Formulation 
Code 
Percent drug release at time (hr) 
1 2 4 6 8 10 12 
F1 54.78±0.912 60.63±0.132 68.05±0.32 79.10±0.478 80.52±0.296 99.63±0.461  
F2 49.26±0.356 59.36±0.204 63.47±0.163 70.42±0.530 84.15±0.174 93.89±0.293 97.26±0.352 
F3 45.15±0.302 51.31±0.106 58.57±0.305 65.05±0.405 75.15±0.540 88.15±0.603 94.89±0.305 
F4 46.00±0.294 50.36±0.100 60.94±0.203 66.47±0.100 79.10±0.192 91.10±0.109 99.47±0.402 
F5 44.36±0.501 49.10±0.329 58.57±0.345 66.47±0.113 75.94±0.183 88.73±0.293 97.42±0.304 
F6 43.15±0.4983 49.10±0.492 57.15±0.941 64.89±0.132 74.21±0.305 84.47±0.309 93.78±0.394 
F7 44.84±0.192 50.56±0.529 60.63±0.183 68.94±0.193 79.42±0.427 90.15±0.509 98.05±0.509 
F8 40.42±0.329 44.84±0.592 57.18±0.192 64.10±0.429 73.19±0.539 86.21±0.513 94.42±0.209 
F9 34.10±0.310 40.73±0.309 50.68±0.391 57.78±0.451 68.46±0.419 80.68±0.319 87.31±0.209 
Theoratical 
Drug 
Release 
47.60 52.29 61.68 66.91 80.45 91.24 99.22 
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formulation. Results of drug release from Formulation 
F4, F5, F6 and formulation F7, F8, F9 follows same 
pattern as of F1, F2 and F3. Percent drug release was 
important factor in optimization of gastroretentive drug 
delivery of Tinidazole. 
 
 
Figure 6: Comparative In Vitro release profile of F1 – F9 Formulation 
Release kinetics 
The release data were analyzed as per Zero order, First 
order, Higuchi‟s and Peppas equation models to know 
the pattern of drug release and mechanism of drug 
release from the Floating  tablets.
 
Table 10: Drug release kinetics of blended formulations: 
Formulation code (R
2
 values) 
 Zero order First order Higuchi 
 
Hixon-
crowell 
Korsmey- 
Peppas 
 
    n 
F1 0.8633 0.9090 0.9612 0.4299 0.9778 0.493 
F2 0.8825 0.9346 0.9665 0.4438 0.9807 0.528 
F3 0.7052 0.9500 0.9638 0.4687 0.9906 0.538 
F4 0.8696 0.9364 0.9648 0.4299 0.9935 0.549 
F5 0.8815 0.9539 0.9667 0.4438 0.9964 0.607 
F6 0.9034 0.9563 0.9697 0.4668 0.9938 0.575 
F7 0.9122 0.9050 0.9772 0.4299 0.9963 0.604 
F8 0.9161 0.9658 0.9797 0.4438 0.9845 0.533 
F9 0.9291 0.9769 0.9867 0.4668 0.9920 0.545 
 
Optimization: 
Table 11: Optimization Table with response variables: 
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F1
f2
F3
F4
F5
F6
f7
F8
F9
Run HPMC 
K15M 
Sodium 
Alginate 
Percent drug release Floating 
lag time Q 1 Hr.  Q 10 Hr. 
1 +1 0 40.22 86.01 34 
2 -1 0 49.00 93.70 18 
3 0 +1 42.98 84.30 28 
4 0 -1 45.80 91.06 18 
5 -1 -1 54.60 99.50 14 
6 +1 +1 34.03 80.50 40 
7 -1 +1 44.95 88.05 22 
8 +1 -1 44.82 90.03 26 
9 0 0 44.22 88.50 22 
10 0 0 44.52 88.96 26 
11 +1 -1 44.86 90.27 30 
12 -1 0 49.52 94.08 20 
13 0 -1 46.20 91.14 22 
14 -1 -1 54.96 99.76 18 
15 -1 +1 45.20 88.25 24 
16 +1 +1 34.17 80.86 44 
17 +1 0 40.62 86.41 38 
18 0 +1 43.17 84.64 32 
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Total amount of tinidazole released from all the 
formulations until 12 hours ranged between 99.99% to 
88.78% indicating almost complete drug release from 
all the formulations. Rate of percent drug release tended 
to decrease with increase in the content of either HPMC 
K15M or Sodium Alginate. This in agreement with 
literature findings that the viscosity of gel layer around 
the Tablet increases with increase in the hydrogel 
concentration,thus limiting the release of active 
ingredient. Although they are described as „soluble‟, 
During swelling state electrostatic repulsion between 
the negatively charged carboxyl groups cause uncoiling 
and gel formation. The gel, thus formed, consists of 
closely packed swollen particles. With further increase 
in polymer amount, thicker gel forms inhibiting water 
penetration more strongly,resulting in significant 
reduction in the values of perecent drug release at 12 
hours. 
Factorial models and Response surface analysis 
i) Response surface plots for measured responses. Q 
1hr (Y1) 
Three-dimensional response surface plots are presented 
in Figure 7 shows that cumulative drug release  
increases with decrease in concentrations of polymer. 
The Contour plots showing the effect of polymer 
concentration on the Y1 (cumulative drug release at 1 
hr) is shown in Figure 7 
 
 
 
Figure 7: Response surface plot of cumulative percent drug release at 1 hours and levels of HPMC K15M and 
Sodium Alginate. 
 
ii) Response surface plots for measured responses. Q 10hr (Y2) 
 
 
Figure 8: Response surface plot of cumulative percent drug release at 10 hours and levels of HPMC K15M and 
Sodium Alginate. 
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iii) Response surface plots for measured responses.(Floating lag time) Y3 
 
Figure 9:  Response surface plot of Floating lag time and levels of HPMC K15M and Sodium Alginate. 
 
Three-dimensional response surface plots are presented in 
Figure 9 shows that Floating lag time increases with 
increases in concentrations of HPMC K15M and Sodium 
alginate. Therefore it can be derived that the change in 
concentration of polymer had significant effect on the 
Floating lag time of the formulation.  
CONCLUSION: 
Regulated drug release in zero-order manner attained in the 
current study indicates that the optimized gastro-retentive 
tablet of Tinidazole, prepared using Sodium Alginate and 
HPMC K15M can successfully be employed as a  oral 
controlled release drug delivery system. High Floating 
ability of the formulation is likely to increase its GI 
residence time, and eventually, improve the extent of 
bioavailability. However, appropriate balancing between 
various levels of the two polymers is imperative to acquire 
proper controlled release and byouncy. 3
2
 factorial design 
is quite efficient in optimizing gastro-retentive drug 
delivery system of Tinidazole. Floating tablet of 
Tinidazole can be successfully employed for eradication of 
H.pylori infection which is main cause of gastric ulcers. 
Gastroretentive dosage form of Tinidazole will reduce the 
frequency of administration of drug and helps to minimize 
dose of drug and side effects associated with the drug. 
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